These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 128484)

  • 1. Lymphocyte function in patients with Hodgkin's disease.
    Rühl H; Vogt W; Rühl U
    G Batteriol Virol Immunol; 1975; 68(1-6):3-16. PubMed ID: 128484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed lymphocyte culture stimulatory and responding capacity of lymphocytes from patients with lymphoproliferative diseases.
    Rühl H; Vogt W; Bochert G; Schmidt S; Moelle R; Schaoua H
    Clin Exp Immunol; 1975 Jan; 19(1):55-65. PubMed ID: 128426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological capacity of lymphocytes from untreated patients with Hodgkin's disease evaluated in mixed lymphocyte culture.
    Björkholm M; Holm G; Mellstedt H; Pettersson D
    Clin Exp Immunol; 1975 Dec; 22(3):373-7. PubMed ID: 131665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte transformation and production of a human mononuclear leucocyte chemotactic factor in patients with Hodgkin's disease.
    Rühl H; Vogt W; Bochert G; Schmidt S; Schaoua H; Moelle R
    Clin Exp Immunol; 1974 Jul; 17(3):407-15. PubMed ID: 4468860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte reactivity to phytohaemagglutinin and allogeneic lymphocytes in 32 untreated patients with Hodgkin's disease.
    Lang JM; Oberling F; Bigel P; Mayer S; Waitz R
    Biomedicine; 1974 Sep; 21(9):372-7. PubMed ID: 4281669
    [No Abstract]   [Full Text] [Related]  

  • 7. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
    Land JM; Litwin J; Bigel P; Oberling F; Mayer S
    Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.
    Hillinger SM; Herzig GP
    J Clin Invest; 1978 Jun; 61(6):1620-7. PubMed ID: 149140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease.
    Pappas A; Pees H; Girmann G
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency disease: impairment of cellular interactions leading to abnormal mediator production in mixed lymphocyte culture reaction.
    Gorski AJ; Dupont B; Hansen JA; Safai B; Pahwa S; Good RA
    J Immunol; 1977 Mar; 118(3):858-62. PubMed ID: 139447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect.
    Björkholm M; Holm G; Mellstedt H; Johansson B; Killander D; Sunblad R; Söderberg G
    Scand J Haematol; 1978 Apr; 20(4):306-18. PubMed ID: 653310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro lymphocyte dysfunction in Hodgkin's disease.
    Graze PR; Perlin E; Royston I
    J Natl Cancer Inst; 1976 Feb; 56(2):239-43. PubMed ID: 130496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
    Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
    Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evidence of normal lymphocyte function in some patients with Hodgkin's disease and negative delayed cutaneous hypersensitivity.
    Churchill WH; Rocklin RR; Moloney WC; David JR
    Natl Cancer Inst Monogr; 1973 May; 36():99-106. PubMed ID: 4583000
    [No Abstract]   [Full Text] [Related]  

  • 16. Production of interleukin-2 and expression of tac antigen in Hodgkin disease.
    Joshi NN; Mukhopadhyay R; Advani SH; Gangal SG
    Cancer Detect Prev Suppl; 1987; 1():137-43. PubMed ID: 2825998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease.
    Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ
    Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of phytohemagglutinin on lymphocytes in Hodgkin's disease].
    Eggerth G; Kühböck J; Pokorny D
    Wien Z Inn Med; 1969; 50(7):314-9. PubMed ID: 5380683
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxic activity of lymphocytes from patients with Hodgkin's disease.
    Holm G; Björkholm M; Mellstedt H; Johansson B
    Clin Exp Immunol; 1975 Sep; 21(3):376-83. PubMed ID: 1081933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of immunocompetence in Hodgkin's disease.
    Faguet GB
    J Clin Invest; 1975 Oct; 56(4):951-7. PubMed ID: 1159096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.